Journal of Autism and Developmental Disorders

, Volume 35, Issue 3, pp 377–385

Clinical Efficacy of Fluvoxamine and Functional Polymorphism in a Serotonin Transporter Gene on Childhood Autism

  • Yoko Sugie
  • Hideo Sugie
  • Tokiko Fukuda
  • Masataka Ito
  • Yumiko Sasada
  • Mutsumi Nakabayashi
  • Kazunobu Fukashiro
  • Takehiko Ohzeki
Article

DOI: 10.1007/s10803-005-3305-2

Cite this article as:
Sugie, Y., Sugie, H., Fukuda, T. et al. J Autism Dev Disord (2005) 35: 377. doi:10.1007/s10803-005-3305-2

Abstract

We studied the correlation between response to fluvoxamine and serotonin transporter gene promoter region polymorphism (5-HTTLPR). Eighteen children with autistic disorder completed a 12-week double-blind, placebo-controlled, randomized crossover study of fluvoxamine. Behavioral assessments were obtained before and at 12 weeks of treatment. 5-HTTLPR (long (l) or short(s)), was analyzed by the PCR method. Ten out of 18 patients responded to fluvoxamine treatment; allele type analysis revealed that clinical global effectiveness was noted significantly more in the l allele than in the s allele. However, with respect to language use, a significant effectiveness was noted in the s allele. 5-HTTLPR may influence the individual responses to fluvoxamine administration.

Keywords

Autistic disorder selective serotonin transporter inhibiter serotonin transporter gene 5-HTTLPR 

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Yoko Sugie
    • 1
    • 2
  • Hideo Sugie
    • 2
  • Tokiko Fukuda
    • 2
  • Masataka Ito
    • 2
  • Yumiko Sasada
    • 3
  • Mutsumi Nakabayashi
    • 3
  • Kazunobu Fukashiro
    • 3
  • Takehiko Ohzeki
    • 1
  1. 1.Department of PediatricsHamamatsu University School of MedicineHamamatsuJapan
  2. 2.Department of Pediatric NeurologyHamamatsu City Medical Center for Developmental MedicineHamakita CityJapan
  3. 3.Division of Clinical PsychologyHamamatsu City Medical Center for Developmental MedicineHamakitaJapan